The average of price targets set by Wall Street analysts indicates a potential upside of 91.1% in Alvotech (ALVO). While the effectiveness of this highly sought-after metric is questionable, the ...

RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.